Skip to main content
TipRanks
Go Ultimate75% OFF

Niagen Bioscience (OCD1) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Niagen Bioscience has a market cap or net worth of EUR 148.36M. The enterprise value is EUR 163.68M.

Market Cap
EUR 148.36M
Enterprise Value
EUR 163.68M

Share Statistics

Niagen Bioscience has 79,196,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
79,196,900
Owned by Insiders
5.07%
Owned by Institutions
29.63%

Financial Efficiency

Niagen Bioscience’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 15.61%.

Return on Equity (ROE)
0.23
Return on Assets (ROA)
0.16
Return on Invested Capital (ROIC)
15.61%
Return on Capital Employed (ROCE)
0.17
Revenue Per Employee
1.11M
Profits Per Employee
148.56K
Employee Count
117
Asset Turnover
1.22
Inventory Turnover
2.26

Valuation Ratios

The current PE Ratio of Niagen Bioscience is 16.31. Niagen Bioscience’s PEG ratio is -0.33.

PE Ratio
16.31
PS Ratio
1.34
PB Ratio
1.97
Price to FCF
35.72
Price to Operating Cash Flow
33.48
PEG Ratio
-0.33

Income Statement

In the last 12 months, Niagen Bioscience had revenue of 129.42M and earned 17.38M in profits. Earnings per share was 0.22.

Revenue
129.42M
Gross Profit
83.19M
Operating Income
14.30M
Pretax Income
18.19M
Net Income
17.38M
EBITDA
19.64M
Earnings Per Share (EPS)
0.22

Cash Flow

In the last 12 months, operating cash flow was 4.88M and capital expenditures -303,000, giving a free cash flow of 4.58M billion.

Operating Cash Flow
4.88M
Free Cash Flow
4.58M
Free Cash Flow per Share
0.06

Dividends & Yields

Niagen Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
2.80%
Earnings Yield
6.27%

Stock Price Statistics

Beta
1.07
52-Week Price Change
-67.76%
50-Day Moving Average
2.19
200-Day Moving Average
2.97
Relative Strength Index (RSI)
46.53
Average Volume (3m)
―

Important Dates

Niagen Bioscience upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 04, 2026
Next Earnings Date
Mar 10, 2027
Ex-Dividend Date
―

Financial Position

Niagen Bioscience as a current ratio of 4.86, with Debt / Equity ratio of 3.68%

Current Ratio
4.86
Quick Ratio
3.83
Debt to Market Cap
0.00
Net Debt to EBITDA
-3.16
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Niagen Bioscience has paid 810.00K in taxes.

Income Tax
810.00K
Effective Tax Rate
0.04

Enterprise Valuation

Niagen Bioscience EV to EBITDA ratio is 13.75, with an EV/FCF ratio of 36.17.

EV to Sales
1.35
EV to EBITDA
13.75
EV to Free Cash Flow
36.17
EV to Operating Cash Flow
33.92

Balance Sheet

Niagen Bioscience has EUR 0.00 in cash and marketable securities with EUR 2.08M in debt, giving a net cash position of -EUR 2.08M billion.

Cash & Marketable Securities
EUR 0.00
Total Debt
EUR 2.08M
Net Cash
-EUR 2.08M
Net Cash Per Share
-EUR 0.03
Tangible Book Value Per Share
EUR 0.98

Margins

Gross margin is 63.86%, with operating margin of 2.28%, and net profit margin of 8.37%.

Gross Margin
63.86%
Operating Margin
2.28%
Pretax Margin
9.04%
Net Profit Margin
8.37%
EBITDA Margin
9.85%
EBIT Margin
8.40%

Analyst Forecast

The average price target for Niagen Bioscience is EUR 7.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 7.40
Price Target Upside
295.62% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
-6.71%
EPS Growth Forecast
-53.86%

Scores

Smart Score
3
AI Score
―